BASEL, Switzerland, and NEW YORK, Nov. 19, 2003 (PRIMEZONE) -- Novartis:
New positive Phase II data on LAF237 (type-II diabetes), SPP100 (hypertension), AAE581 (osteoporosis) and QAB149 (asthma and chronic obstructive pulmonary disease) Build-up of Novartis Institutes of BioMedical Research on track for completion in second quarter of 2004 Full pipeline includes 10 new medicines in late-stage development with peak sales potential in excess of USD 10 billion and 78 development projects in total
At its 2003 R&D Day in New York today Novartis unveils its pharmaceutical pipeline, which has been hailed as one of the strongest in the industry and is focused on attractive market segments and a broad range of unmet medical needs.
Please find full press release under the following link: http://hugin.info/134323/R/925519/126007.pdf